{
    "2020-06-29": [
        [
            {
                "time": "2023-10-01",
                "original_text": "Novartis Gets Positive CHMP View for Cosentyx Label Expansion",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Positive",
                        "CHMP",
                        "Cosentyx",
                        "Label Expansion"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "NVS Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Novartis AG and Encourages Investors to Contact the Firm",
                "features": {
                    "keywords": [
                        "Investor Alert",
                        "Bronstein",
                        "Gewirtz & Grossman",
                        "LLC",
                        "Investigation",
                        "Novartis AG"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "legal",
                        "investments"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Race for a COVID-19 vaccine has drug makers scaling up manufacturing — before one is developed",
                "features": {
                    "keywords": [
                        "COVID-19",
                        "vaccine",
                        "drug makers",
                        "manufacturing",
                        "scaling up"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "These 6 health-care stocks are ‘buys’ because they can thrive under either Trump or Biden",
                "features": {
                    "keywords": [
                        "health-care",
                        "stocks",
                        "buys",
                        "Trump",
                        "Biden"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "politics"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Japan's Takeda expects $200 million operating loss related to Novartis' Xiidra withdrawal",
                "features": {
                    "keywords": [
                        "Japan",
                        "Takeda",
                        "operating loss",
                        "Novartis",
                        "Xiidra",
                        "withdrawal"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}